Acadia Pharmaceuticals CEO Uli Hacksell speaks at the Jefferies 2013 Global Healthcare Conference in New York, June 5, 2013. (ACHC) CEO Debra Osteen

22 Dec 2015 Uli Hacksell, Cerecor's chairman, will become president and CEO, effective Jan. 1. Previously CEO of San Diego-based Acadia Pharmaceuticals

Som vd för San Diego-baserade ACADIA Pharmaceuticals (2000-2015) ledde han utvecklingen från privat start-up företag till publikt mångmiljardbolag och framtagandet av det första och enda godkända läkemedlet mot psykos hos Parkinsonpatienter. ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule darugs for the treatment of central nervous system disorders. For further information please contact: Uli Hacksell, Ph.D., Chief Executive Officer, or Thomas H. Aasen, Vice President and Chief Financial Officer, both of ACADIA Pharmaceuticals Inc., +1-858-558 Uli Hacksell CERC stock SEC Form 4 insiders trading. Uli has made over 22 trades of the Cerecor Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Uli bought 20,000 units of CERC stock worth $15,000 on 10 December 2016. 2021-04-07 · Uli Hacksell Hacksell, född 1950, har under 30 år arbetat inom farmaceutisk industri och bioteknikbolag. Som vd för San Diego-baserade ACADIA Pharmaceuticals (2000-2015) ledde han utvecklingen från privat start-up företag till publikt mångmiljardbolag och framtagandet av det första och enda godkända läkemedlet mot psykos hos Parkinsonpatienter. Dr. Uli Hacksell är sedan 3 maj 2018 styrelseledamot i Medivir och har en bakgrund från över 25 år i ledande befattningar på stora läkemedels- och bioteknikföretag och över 10 års erfarenhet som vd för publika bolag.

Uli Hacksell has over 20 years of international management experience from both large pharmaceutical and biotech companies. He was the CEO of ACADIA Pharmaceuticals from September 2000 to March 2015, and led the company from a private start-up to becoming a public … The estimated Net Worth of Uli Hacksell is at least $65.8 Mille dollars as of 10 December 2016. Uli Hacksell owns over 20,000 units of Cerecor Inc stock worth over $65,800 and over the last 17 years Uli sold CERC stock worth over $0.Cerecor Inc stock worth over $65,800 and over the last 17 years Uli sold CERC stock worth over $0. Which company executives are buying and selling shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) stock? View the most recent insider trading activity for ACAD stock at MarketBeat. The estimated Net Worth of Uli Hacksell is at least $64.2 Tausend dollars as of 10 December 2016.

Uli has made over 22 trades of the Cerecor Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Uli bought 20,000 units of CERC stock worth $15,000 on 10 December 2016.

4 Sep 2014 Therapy designation to Acadia Pharmaceuticals' Nuplazid (Pimavanserin) for disease psychosis,” said Uli Hacksell, Ph.D., CEO of Acadia.

Uli Hacksell - Chief Executive Officer 2018-06-29 · Marina Biotech Appoints Uli Hacksell, Ph.D. and Robert C. Moscato to Board of Directors. Dr. Hacksell served as the Chief Executive Officer and as a director of ACADIA Pharmaceuticals Inc. Uli Hacksell is considered to be independent in relation to the company as well as its senior management and in relation to major shareholders. “Uli Hacksell has tremendous experience of scaling life science companies and is highly regarded for his broad knowledge based on his past leading positions at US-based ACADIA Pharmaceuticals and Cerecor, as well as his time at Astra.

9 juli 2015 - InDex Pharmaceuticals meddelade idag att Uli Hacksell och Jesper Han var VD för amerikanska ACADIA Pharmaceuticals från

Uli Hacksell is listed as an insider in the following companies: CERC / Cerecor Inc. ACAD / ACADIA Pharmaceuticals, Inc. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. ACADIA Pharmaceuticals Inc. 2004 EQUITY INCENTIVE PLAN. 2004 EMPLOYEE STOCK PURCHASE PLAN (Full Titles of the Plans) Uli Hacksell, Ph.D. President and Chief Executive Officer .

Som vd för ACADIA Pharmaceuticals 2000-2015 ledde Hacksell utvecklingen från privat start-up företag till publikt mångmiljardbolag.
Traditionella svenska namn

References ACADIA Pharmaceuticals (NASDAQ:ACAD) Q3 2013 Earnings Call November 6, 2013 5:00 PM ET. Executives.

"We are delighted to complete this financing with such an outstanding syndicate of investors," said Uli Hacksell, Ph.D., ACADIA's Chief Executive Officer. Dr. Hacksell serves as Chairman of the Board of Directors, a position he has held since July of 2018. Dr. Hacksell served as Chief Executive Officer of ACADIA Pharmaceuticals, Inc., or ACADIA, from September 2000 to March 2015 and was a member of its Board of Directors. ACADIA Pharmaceuticals Inc. 2004 EMPLOYEE STOCK PURCHASE PLAN (Full Title of the Plan) Uli Hacksell, Ph.D.
Pia lundqvist gih

gallup nm weather
moped 1970
test driven development advantages and disadvantages
trängselavgift tider
kvinnokliniken danderyd
grattis till studenten tal
smart psykiatri kostnad

6,5 miljoner kronor till Nasdaq-noterade Acadia Pharmaceuticals, vars Vd:n för bolaget heter sedan åer 2000 Uli Hacksell och är före detta

He was succeeded by Uli Hacksell, who left Acadia to lead Cerecor at the beginning of 2016. References ACADIA Pharmaceuticals (NASDAQ:ACAD) Q3 2013 Earnings Call November 6, 2013 5:00 PM ET. Executives. Lisa Barthelemy - Director of Investor Relations.